By Melissa Wildstein | President & Founder, The Matchstick Group | 15+ years in medical device marketing
Last Updated: February 2026
The regulatory pathway your medical device follows—510(k) clearance or PMA approval—fundamentally shapes your marketing timeline, your budget, your messaging strategy, and the type of evidence you can use to sell. A 510(k) device typically has 3–6 months to build commercial readiness around a faster regulatory cycle. A PMA device often has 2–3 years of clinical trial activity that can be leveraged for pre-market awareness—but comes with stricter promotional constraints and significantly higher commercial investment requirements.
Most content comparing 510(k) and PMA focuses on the regulatory process itself: what to submit, how long FDA review takes, what evidence is required. That’s important, but it’s not the question that keeps marketing leaders up at night. The question that matters is: how does my regulatory pathway change what I can do, when I can do it, and how much it will cost to bring this device to market?
That’s what this guide addresses. For the broader launch framework, see our Complete Guide to Medical Device Product Launch Marketing. For what to complete before you go to market regardless of pathway, see our Pre-Launch Marketing Checklist.
What’s the Difference Between 510(k) and PMA—in Plain English?
Before we get into the marketing implications, let’s establish the fundamentals. These two pathways exist because the FDA classifies medical devices by risk level, and different risk levels require different levels of proof before a device can be sold in the United States.
510(k) clearance: “Substantially equivalent”
The 510(k) pathway is for devices that are substantially equivalent to something already legally marketed—a predicate device. Most Class II (moderate-risk) devices go through this route. Think surgical instruments, diagnostic equipment, powered wheelchairs, sutures, and imaging accessories. The FDA reviews the submission to confirm that the new device has the same intended use and similar technological characteristics as the predicate. Clinical data is sometimes required but often not—bench testing and performance data are typically sufficient.
The FDA processes roughly 3,000–3,300 510(k) submissions per year. Review times are officially 90 days, but the full process—including any requests for additional information—typically runs 3–6 months from submission to clearance.
PMA approval: “Proven safe and effective”
The PMA pathway is for Class III (high-risk) devices—typically implants, life-sustaining devices, or devices with no substantial equivalent on the market. Think pacemakers, drug-eluting stents, total joint replacements, and novel diagnostic platforms. PMA requires comprehensive scientific evidence of safety and effectiveness, which almost always means clinical trials. The FDA has 180 days to review a PMA application, but the total process—including clinical trials, pre-submissions, and review cycles—typically spans 2–4 years.
510(k) vs. PMA: The Marketing Impact at a Glance
| Marketing Dimension | 510(k) Device | PMA Device |
|---|---|---|
| Total timeline to market | 12–18 months (submission to commercial launch) | 3–5 years (clinical trial initiation to commercial launch) |
| Marketing planning window | 3–6 months of compressed commercial preparation | 12–24+ months to build awareness during clinical trial phase |
| Clinical evidence at launch | Bench/performance data; limited or no clinical trial data | Robust clinical trial data; publishable results |
| Messaging constraints | Must stay within cleared indications; differentiation claims need careful substantiation | Can leverage clinical trial results but subject to strict FDA-approved labeling language |
| Competitive positioning | Entering established category with existing competitors; must differentiate within predicate framework | Often creating or redefining a category; can lead with clinical data advantage |
| KOL engagement | Build relationships post-clearance; limited pre-market clinical involvement | Clinical investigators become natural advocates; relationships built during trials |
| Budget range (Year 1 marketing) | $250K–$1M+ (startup); 8–15% of revenue (established) | $1M–$5M+ (reflecting higher ASP, broader launch, clinical marketing requirements) |
| Sales model | Often starts with distributors or independent reps; hybrid common | Typically requires direct, specialized sales force with clinical training capability |
| Reimbursement complexity | Usually maps to existing CPT/HCPCS codes | May require new code development; coverage decisions can gate adoption |
How Does a 510(k) Pathway Shape Your Marketing Timeline?
The 510(k) pathway creates a compressed commercial timeline. Because the regulatory process is faster and less resource-intensive than PMA, many companies underestimate how quickly the marketing window opens—and how ready they need to be when it does.
The 510(k) marketing paradox
The speed of the 510(k) pathway is both its greatest commercial advantage and its greatest commercial risk. You get to market faster—but you have less time to prepare. And because you’re entering an established category with existing competitors, you can’t afford a slow start. The market won’t wait for you to figure out your messaging, build your sales toolkit, or get your website live. Your competitors are already there, already positioned, already talking to your target customers.
What your marketing timeline should look like
- 12–18 months before anticipated clearance: Begin customer research, competitive analysis, and brand development. This is when you should be running your 3V Workshop or equivalent strategic planning process. Understand the full decision-making unit, validate your assumptions about the buyer journey, and uncover the hidden audiences and workflow requirements that will shape your positioning.
- 6–12 months before clearance: Finalize positioning and messaging, begin building sales enablement materials, develop website and digital infrastructure, start SEO and disease-state awareness content. If you’re planning a conference launch, this is when booth design, pre-show outreach strategy, and meeting scheduling should begin.
- 3–6 months before clearance: Complete sales training, build paid media campaigns (ready to activate at clearance), finalize trade show materials, draft press release and PR assets, submit initial marketing materials through MLR review. Your claims matrix should be locked and your regulatory review workflow should be running.
- At clearance: Deploy press release, activate paid media, launch product website, begin sales outreach. If you’ve done the pre-work, you should be commercially active within 2–4 weeks of receiving your clearance letter.
🔥 The 510(k) Marketer’s Biggest Mistake
Waiting for clearance to start marketing planning. We see this constantly: the regulatory team submits the 510(k), the company waits for the clearance letter, and then marketing gets the call to “start working on the launch.” By that point, you’ve already lost 3–6 months of commercial preparation time. The companies that launch successfully are the ones that treat the 510(k) submission date as the starting gun for marketing execution—not the clearance date.
How Does a PMA Pathway Shape Your Marketing Timeline?
The PMA pathway creates a fundamentally different marketing dynamic. The longer regulatory timeline, the clinical trial process, and the depth of evidence generated all provide opportunities that 510(k) marketers simply don’t have—but they also introduce constraints and costs that require a different strategic approach.
The PMA marketing advantage: time and evidence
A PMA device spends years in clinical trials before reaching market. During that time, the company has the opportunity to build deep relationships with clinical investigators (who often become your most powerful advocates), generate publishable clinical data (which becomes your most compelling marketing asset), and build disease-state awareness that primes the market for your eventual commercial launch. When done well, a PMA device can launch into a market that’s already educated about the clinical problem and already aware that a new solution is coming.
The PMA marketing constraint: promotional limitations
During clinical trials, you cannot promote your device. Period. Disease-state awareness campaigns are permissible, but they must be carefully constructed to avoid any implication that a specific product is available or superior. This requires marketing teams that understand the line between education and promotion—and regulatory counsel that can review content with that distinction in mind. Post-approval, your promotional claims are tightly bound to your FDA-approved labeling. You have more clinical evidence to work with, but less flexibility in how you use it compared to a 510(k) device.
What your marketing timeline should look like
- During clinical trials (2–3 years before launch): Invest in disease-state awareness content, build relationships with clinical investigators, begin brand development, establish your digital presence, and create an SEO foundation around the clinical problem your device addresses. Engage key opinion leaders through advisory boards and clinical education programs. This phase is about building the audience and the authority so that when approval comes, the market is ready.
- 12–18 months before anticipated approval: Begin commercial planning in earnest. Develop your value proposition and messaging architecture, design your sales model, build the sales enablement toolkit, plan your conference launch strategy, and begin market access and reimbursement planning. If a new CPT code is needed, that process should already be underway.
- 6–12 months before approval: Hire and train your sales team, build your demand generation infrastructure, prepare clinical evidence marketing assets (white papers, case study templates, publication strategy), and align with your clinical affairs team on post-approval study plans that will generate the next wave of marketing evidence.
- At approval: Execute a coordinated, multi-channel launch: press coverage, conference presence, HCP outreach, sales activation, digital campaigns, and investor communications (for publicly traded or PE-backed companies). The PMA approval itself is a newsworthy event—use it.
What About the De Novo Pathway?
The De Novo classification process deserves a mention because it occupies a middle ground that creates its own unique marketing challenges. De Novo is designed for novel, low-to-moderate risk devices that don’t have a predicate—so they can’t go through 510(k)—but don’t carry the risk profile that requires PMA.
From a marketing perspective, De Novo devices face an interesting positioning challenge: you’re creating a new device category, which means there’s no established market to enter and no incumbent competitor to displace. That’s a branding and market education challenge, not a competitive differentiation challenge. Your marketing investment will skew heavily toward disease-state education, clinical workflow integration storytelling, and building the economic case for a procedure or treatment approach that may not yet exist in your target facilities.
The regulatory timeline for De Novo is less predictable than either 510(k) or PMA—FDA review can take 6–12 months or longer—so your marketing planning needs to account for greater timing uncertainty. Build modular commercial assets that can be deployed whenever authorization arrives, rather than planning around a specific launch date.
What Do 510(k) and PMA Marketing Strategies Have in Common?
Despite the significant differences in timeline, evidence, and constraints, the core principles of effective medical device marketing apply regardless of your regulatory pathway.
- Customer insight comes first. Whether you’re launching a 510(k) surgical instrument or a PMA implantable, you need to understand the full decision-making unit, the clinical workflow, and the unstated barriers to adoption. That research shapes everything downstream.
- Your brand is your first impression. In medtech, credibility is a prerequisite. A device with a strong, professional brand identity is taken more seriously by clinicians, administrators, and investors alike. Brand development should happen early regardless of pathway.
- Sales enablement determines adoption speed. The quality of your sales toolkit and the depth of your rep training directly correlate with how quickly your device moves from evaluation to purchase order. This is true for a Class II device sold through distributors and a Class III device sold through a direct clinical sales team.
- Marketing should never wait for regulatory. This is the single biggest lesson we’ve learned across more than 50 medical device launches. The companies that commercialize successfully are the ones that run marketing planning in parallel with the regulatory process—not in sequence after it. The regulatory pathway determines your timeline constraints. Your marketing strategy should fill every available minute of that timeline with purposeful commercial preparation.
🔥 TMG’s Approach: Pathway-Specific Launch Planning
At The Matchstick Group, we tailor our launch engagements to the regulatory pathway. Our Accelerate program is built for 510(k) companies facing a compressed timeline—a 90-day sprint that prioritizes the highest-impact commercial assets. Our Launch program is designed for companies with a longer runway—whether PMA, De Novo, or 510(k) with extended planning—that need a comprehensive, phased marketing buildout from strategy through execution. Both programs start with customer insight and end with measurable commercial traction.
How Should Your Regulatory Pathway Influence Your Marketing Budget?
Budget is one of the most practical questions marketing leaders face, and your regulatory pathway has a direct impact on the answer.
510(k) device budgeting
For a startup launching a 510(k) device, plan to allocate 15–25% of Year 1 projected revenue to marketing, with a typical investment range of $250K–$1M+. Because the commercial window is compressed, a higher proportion of that budget should be front-loaded into pre-clearance preparation: brand development, sales enablement, digital infrastructure, and campaign readiness. Post-clearance spend shifts toward demand generation, trade show execution, and clinical evidence marketing as early data becomes available.
PMA device budgeting
PMA devices require substantially higher marketing investment—typically $1M–$5M+ in Year 1—reflecting larger sales teams, broader geographic launch plans, clinical marketing complexity, and the need for robust market access and reimbursement support. However, the longer pre-approval timeline allows you to spread investment over a longer period. Disease-state awareness, KOL engagement, and brand development can begin years before approval, with the heaviest commercial spending concentrated in the 12 months surrounding the approval event.
In both cases, the most expensive mistake is underinvesting in pre-market preparation and overinvesting in post-market demand generation. A dollar spent on positioning, messaging, and sales readiness before launch generates more return than a dollar spent on paid media after launch with unclear positioning and unprepared reps.
Frequently Asked Questions
Can I market my medical device before FDA clearance or approval?
How long does it take to get a 510(k) cleared vs. a PMA approved?
Which pathway gives me a stronger marketing position at launch?
What is the De Novo pathway and how does it affect marketing?
How much more does it cost to market a PMA device vs. a 510(k) device?
Navigating a 510(k) or PMA Launch?
At The Matchstick Group, we’ve built marketing strategies for medical devices across every major regulatory pathway—510(k), PMA, De Novo, and international equivalents. We know how to calibrate commercial planning to your specific regulatory timeline, and we understand the messaging constraints and evidence requirements that each pathway creates. Whether you’re 90 days from a 510(k) clearance or 18 months from a PMA decision, we can help you build the commercial foundation that turns regulatory authorization into market adoption.
Schedule a call to discuss your regulatory pathway and marketing timeline.
